The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.

The present disclosure provides methods and compositions for controlling the localization of proteins in lipid structures. The disclosure also provides methods for selecting appropriate proteins for desired localization and distribution in lipid structures based on hydrophobic thickness.

Some embodiments of the present application are related to multivesicular liposome formulations comprising high concentration of bupivacaine for the purpose of preventing, treating or ameliorating pain, for example, post-surgical pain for an extended period of time. Processes of making and administering bupivacaine encapsulated multivesicular liposome formulations (BUP-MVLs) and their uses as medicaments are also provided.

The disclosure generally relates to lipid nanodiscs, in particular to lipid nanodiscs formed from polymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and a polymer encircling the hydrophobic edge of the lipid bilayer. The polymer includes a first monomeric unit having a pendant hydrophobic group and a second monomeric unit having a backbone hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

The aspects of the disclosed embodiments relate to exosome systems and compositions and preservative systems and compositions including systems and compositions including diatomic oxygen as well as methods of use and methods of manufacturing of them.

This disclosure provides an exosome mimicking nanovesicle (EMN) comprising cell-derived plasma membrane or lipid rafts and substantially devoid of native exosomes. The EMNs can be derived from a differentiated cell or a stem cell. They are useful to carry a variety of cargo, e.g., a secretome, or exogenous agent selected from a polynucleotide, a peptide, a protein, an antibody fragment, a chemical, or a therapeutic agent. They are useful for the treatment of a variety of diseases and disorders.

Provided is a liposomal sustained release composition of bronchodilator for use in treatment of pulmonary disease. The liposomal bronchodilator has a liposome containing a bronchodilator entrapped in the liposome. The bronchodilator has been stably encapsulated in the liposome, and the resulting liposomal bronchodilator is proven to be stably aerosolized or nebulized for administration via the inhalation route to treat a subject in need thereof.

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.